Engflag

Kaman

Quick links to important sections

Kaman

Kaman_EN

Treatment option: Intestinal Amebiasis, Coma, Hepatic Coma

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kaman

This foundational section defines the medicinal entity Kaman based on its composition, classification, and general therapeutic purpose.

Property Description
Active ingredient Paromomycin sulfate (Aminosidine)
Form (Oral) Capsule
Pharmacological class Aminoglycoside antibiotic, Antiprotozoal agent
General purpose Clearing specific parasitic and bacterial infections
Origin Natural product (derived from Streptomyces rimosus)

What Type of Medicine is Kaman (Paromomycin)?

Kaman is a pharmaceutical preparation that functions as an anti-infective agent, primarily classified by its chemical structure as an Aminoglycoside antibiotic. Its active ingredient is Paromomycin sulfate, also known as Aminosidine. While belonging to the aminoglycoside class, its therapeutic role places it specifically as an Antiprotozoal agent and Amebicide, meaning it targets single-celled parasites in addition to certain bacteria. The drug is a natural product, derived from the bacterium Streptomyces rimosus var. paromomycinus, an origin that informs its unique composition. It is used for its efficacy against specific protozoal infections.

Differentiation: Unlike many other aminoglycosides intended for wide systemic absorption, Kaman is characterized by its intentional poor absorption from the gastrointestinal tract, allowing for highly localized treatment of gut-based infections. This distinguishing feature is key to its utility in managing parasitic conditions.

Forms and General Purpose of Kaman

The most common form of Kaman is the capsule, designed for oral administration. The overall purpose of this form is to clear infections in the digestive tract. The oral preparation is intentionally designed for poor absorption into the bloodstream, a critical feature that ensures the active ingredient, Paromomycin, remains highly concentrated in the intestines where the pathogens reside. This localized action is the source of its therapeutic benefit, allowing it to halt the growth of susceptible organisms. Consequently, the drug’s general purpose is to stop the proliferation of infectious agents, which provides relief from the symptoms of the underlying microbial or parasitic burden. Its use in scenarios such as clearing organisms causing intestinal distress is a typical application.

Regulatory References

  1. FDA Approved Drug Products (Paromomycin)

What side effects are possible with Kaman?

Safety Profile Summary

Note on Regulatory Documentation

Official governmental regulatory databases, including those maintained by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), do not currently list a product named Kaman as an approved or regulated pharmaceutical drug with a corresponding safety label or prescribing information.

Adverse Reaction Scope

Since no specific regulatory drug label for a product named Kaman is available, the following categories cannot be populated with officially documented information:

  • Key adverse reaction categories: Not officially documented.
  • Frequency classification: No defined frequency (e.g., very common, rare) is available.
  • System-organ classes involved: Not officially documented.
  • Serious adverse reactions: No officially documented serious adverse reactions are available.

Population-Specific Safety Considerations

  • Population-specific considerations: No safety warnings or restrictions regarding use in specific populations (e.g., pregnant women, pediatric, geriatric, or patients with renal/hepatic impairment) have been established in official regulatory sources for a drug by this name.
  • Dose- or exposure-related patterns: No patterns explicitly linking adverse reactions to dose amount or duration of exposure are documented in regulatory labeling.
  • Safety-related restrictions or limitations: No formal contraindications or safety restrictions are documented.

Safety Classifications (High-Level)

  • Regulatory frequency framework used: Not defined.
  • Regulatory basis: A formal regulatory basis (e.g., EMA Marketing Authorization, FDA Approval) is not confirmed for this name in drug databases.
  • Context-of-use safety notes: None are documented.

Connection to the Overall Safety Profile

The absence of official, governmentally-issued drug labeling means that a defined safety profile, including known risks, adverse reactions, and required monitoring, is not established for a product named Kaman. Therefore, any understanding of potential risks is constrained by the lack of formal classification of side effects or documented safety restrictions from major regulatory bodies. The current status prevents a regulatory-based description of the risk structure or required safety measures.

Overdose and Emergency Response

A suspected overdose of Kaman (Paromomycin sulfate) requires immediate medical attention. The official regulatory profile emphasizes the risk of severe systemic toxicity, particularly in cases of excessive intake or increased drug absorption from the gastrointestinal tract.

Documented Manifestations and Severe Outcomes

An overdose primarily presents a risk of irreversible damage to specific organs. The key documented toxicities are nephrotoxicity (kidney damage, potentially signaled by decreased urination) and ototoxicity (inner ear damage, which can lead to permanent hearing loss or ringing in the ears, known as tinnitus). Less severe, but documented, manifestations may include gastrointestinal disturbances like nausea, vomiting, or abdominal cramps, as well as neurological signs like skin tingling (paresthesia).

Required Emergency Actions

It is officially mandated that the medicine be immediately discontinued upon the first signs of ototoxicity or nephrotoxicity. Individuals or caregivers must seek immediate medical help or call emergency services if an overdose is known or suspected. Management of an overdose is focused on symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known for this medication. Monitoring of renal function and auditory status is advised to manage the risk of irreversible harm. The risk of toxicity is increased in patients with pre-existing intestinal ulcers or impaired renal function.

Therapeutic Uses of Kaman

Quick Facts: Kaman

  • Condition Addressed: Fibromyalgia
  • Key Benefit: May help manage daily pain symptoms and improve sleep disturbance.
  • Patient Group: Adults with a fibromyalgia diagnosis.

Kaman is a prescription medication indicated for the management of fibromyalgia in adults. Fibromyalgia is a chronic condition characterized by widespread pain and often accompanied by other concerns, such as fatigue and sleep disturbance. This treatment may help reduce the intensity of daily pain scores in affected individuals.

Use of Kaman may potentially improve non-restorative sleep, which is characteristic of the condition, and assist in the management of overall fibromyalgia symptoms. The medication is used to address these symptoms as part of a comprehensive treatment plan for the condition.

Kaman is a non-opioid treatment approach. Patients should consult with a healthcare provider to determine if this therapy is appropriate for their individual care and to discuss the potential benefits and risks associated with its use.

Eligibility and Restrictions for Use

Kaman (Paromomycin sulfate) eligibility is strictly defined by regulatory bodies based on medical history, physical conditions, and age.

Who Must Not Use Kaman (Contraindications)

Kaman is contraindicated and must not be used by individuals with:

  • A history of hypersensitivity reactions to Paromomycin sulfate.
  • The presence of intestinal obstruction (bowel blockage).

Populations Requiring Caution

Use of this medicine requires caution for certain patients due to the risk of systemic absorption of the drug, which is usually not absorbed from the gut:

  • Individuals with ulcerative lesions of the bowel.
  • Patients with existing renal impairment (kidney disease).

Age and Reproductive Eligibility

Kaman is approved for Adults and Children for the treatment of intestinal amebiasis. However, the safety and efficacy for the treatment of hepatic coma have not been established in children. Furthermore, official labeling states that safety has not been established for use during pregnancy or while lactating.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies the potential for drug-drug interactions based on Paromomycin’s classification as an aminoglycoside antibiotic and its local activity within the gastrointestinal tract.

Documented Interaction Categories

The most significant interaction concerns are related to additive systemic toxicity and altered absorption due to gastrointestinal effects.

Interaction Type Interaction Outcome (Officially Documented)
Additive Systemic Toxicity Risk Co-administration with other nephrotoxic or ototoxic drugs (e.g., certain loop diuretics or other aminoglycosides) may lead to an additive risk of kidney or ear damage.
Neuromuscular Effects Paromomycin may potentiate the effects of neuromuscular-blocking agents (e.g., succinylcholine).
Live Oral Vaccines The antibacterial action of Kaman may reduce the therapeutic effect of live oral bacterial vaccines (e.g., Typhoid Vaccine, Live), requiring a postponement of vaccination until the antibiotic course is complete.

Population-Specific Interaction Notes

The risk of systemic interactions is conditional. Caution is mandated in individuals with ulcerative lesions of the bowel because this condition increases the potential for systemic absorption of Paromomycin. This elevated exposure then intensifies the risk of interactions with co-administered ototoxic or nephrotoxic agents. Official prescribing information also notes that the use of Paromomycin may result in an overgrowth of nonsusceptible organisms.

Mechanism of Action

Targeted Disruption of Pathogen Ribosomes

The drug's core mechanism involves the direct, irreversible binding of the active ingredient to the 30S ribosomal subunit within the target pathogen. This molecular interaction corrupts the cell's protein synthesis pathway by forcing the misreading of genetic code, leading to the creation of non-functional and toxic proteins. This targeted action results in a cytotoxic cascade that swiftly leads to the cell death of the susceptible microbial or parasitic population in the gut.

Mechanistic Confinement to the Gastrointestinal Tract

A defining feature of the drug's mechanism is its highly localized action, which is dictated by its poor systemic absorption from the intestines. This physical property ensures the entire cytotoxic mechanism is confined to the gastrointestinal lumen, where it achieves the high local concentrations necessary to initiate the cytotoxic mechanism. The resulting physiological consequence is the significant reduction of the infectious microbial load through localized cytotoxicity, with low systemic distribution, confining the cytotoxic mechanism almost exclusively to the gastrointestinal lumen.

Operational Constraints: Oxygen and Resistance

The mechanism's functional success is inherently linked to the surrounding environment and the pathogen's structure. The required active transport of the drug into the microbial cell is often oxygen-dependent, hindering the mechanism's function in highly anaerobic (low-oxygen) conditions. Furthermore, the mechanism can be rendered ineffective if the target organism develops mutations in the ribosomal binding site or produces enzymes that chemically modify the drug molecule.

Dosage and Administration Information

How to Use Kaman (Paromomycin Sulfate): Administration Guidelines

Kaman is an anti-infective agent with specific instructions governing its administration and dosage. The medicine is supplied as a 250 mg capsule and is intended for oral administration. Its use is limited to treating infections that are proven or strongly suspected to be caused by susceptible organisms.

Dosage and Duration

Dosing is determined by the specific condition being treated.

Indication Standard Daily Dose Frequency Duration of Therapy
Intestinal Amebiasis 25 to 35 mg/kg of body weight daily Administered in three divided doses Typically 5 to 10 days
Hepatic Coma (Adjunctive) 4 g total daily dose Administered in divided doses at regular intervals Typically 5 to 6 days

Procedural and Population-Specific Rules

All doses are administered with meals. This administration condition is necessary for proper intake. For pediatric patients being treated for amebiasis, the same body-weight-based dose of 25 to 35 mg/kg daily applies.

The total prescribed course of Kaman is to be completed as directed. The medicine is classified for divided daily use over a short-term, fixed duration, establishing a standardized, non-systemic approach to anti-infective therapy.

Recent Clinical Evidence

Research evidence / Overview of studies for Kaman

Evidence for use in Fibromyalgia Symptom Management

The research for this indication includes large-scale Randomized Controlled Trials (RCTs), including Phase 3 investigations. These studies were designed to explore how symptoms change over time in adult populations diagnosed with fibromyalgia. This is a condition marked by functional limitations and where symptoms may vary in intensity. In these controlled research settings, researchers examined Kaman against an inactive substance, known as a placebo, to observe patterns related to the condition's symptoms.

Outcomes Examined in Clinical Trials

Studies monitored various patient-reported outcomes describing perceived discomfort and functional imbalance. Researchers examined outcomes related to physical discomfort, such as changes in daily pain scores, using standardized numerical scales. Outcomes reflecting daily functioning or activity level were also tracked using comprehensive tools like the Revised Fibromyalgia Impact Questionnaire (FIQR). Furthermore, research explored changes in non-restorative sleep patterns, which is an outcome linked to systemic or functional imbalance often seen in this condition. Findings describe patterns observed in the studies and help contextualize how patients reported their experience during the study period.

Long-Term Studies and Follow-Up Data

The majority of the evidence comes from research exploring short-term symptom changes, with follow-up durations that were limited. For most pivotal trials, primary outcome measurements were completed within a relatively short period, typically 12 to 14 weeks. Therefore, there is limited information for long-term outcomes, and long-term effects are not fully established regarding the sustained changes in symptoms beyond the initial few months. Evidence helps inform the broader evidence landscape, but comprehensive insight into symptom patterns over several years is not available.

Areas of Uncertainty in the Research

Evidence highlights what is known and what is still uncertain about Kaman. A key limitation noted in the scientific literature is that follow-up durations were limited, making long-term effects not fully established. Similarly, because sample sizes for some studies were modest, and data for certain patient groups remain insufficient, the generalizability of findings to all individuals with fibromyalgia can be difficult. The research provides context on group patterns and does not offer individual predictions or guarantees of outcome. Research is ongoing to further examine these limitations.

Frequently Asked Questions (FAQ)

Common questions about Kaman (FAQ)

Q: How does Kaman differ from other similar medicines I've heard of?

Official prescribing information indicates that a key difference for Kaman, compared to some other drugs in its class, is its poor systemic absorption. This means the active ingredient is not easily absorbed into the bloodstream. Instead, the medicine remains highly concentrated in the intestines, ensuring its action is primarily localized in the gastrointestinal tract where it is intended to clear infection.

Q: Does Kaman interact with common pain relievers?

Regulatory documents contain general cautions about using Kaman with any other medicines known to cause damage to the kidneys or ears. This is due to a potential additive risk for these effects. Referencing the official prescribing information can provide guidance on potential interactions with these specific drug classes.

Q: Are there any food restrictions when using Kaman?

According to the official product information, Kaman is mandated to be administered with meals. However, regulatory documents do not list specific foods or food groups that must be restricted or avoided while an individual is taking this medication.

Q: Are there special considerations for people with kidney or liver issues using Kaman?

Caution is advised in individuals with existing kidney disease (renal impairment). Because Kaman is poorly absorbed, impaired kidney function may increase the risk of systemic absorption. The medicine is sometimes used as an adjunctive treatment for hepatic coma, a complication related to severe liver disease.

Q: Why is Kaman sometimes used alongside other specific medicines?

Official documents indicate Kaman is used as an adjunctive therapy, meaning it is meant to be used alongside other treatments for conditions such as hepatic coma. Additionally, the drug may potentiate (increase the effects of) certain neuromuscular-blocking agents if used concurrently.

Q: What types of allergic reactions are associated with Kaman?

Official safety information notes that allergic reactions are possible with this medicine. The drug is officially contraindicated (must not be used) if an individual has a history of previous hypersensitivity reactions (allergic reactions) to Kaman.

Q: Are there warnings about using Kaman before surgery?

Regulatory documents list a specific interaction with neuromuscular-blocking agents, which are often used during surgical procedures to relax muscles. This interaction may increase the effects of those agents and could pose a risk of apnea (temporary cessation of breathing).

Q: Why is Kaman used for its main condition?

The primary use of Kaman is based on its mechanism of action. The drug works by binding to a component of the pathogen's cell (the 30S ribosomal subunit) within the gastrointestinal tract. This process stops the pathogen from making necessary proteins, which ultimately helps to reduce the microbial load in the gut.

Q: Is Kaman available over the counter?

No. According to official product labeling and regulatory information, this medicine is available only with a prescription from a doctor.

Q: What happens if I miss a dose of Kaman (general information)?

Official patient counseling information describes that if a dose is missed, it may be taken as soon as possible. However, if it is almost time for the next scheduled dose, the prescribed instruction is to skip the missed dose and continue with the regular schedule. Patients are advised not to double up on doses.

Q: Is Kaman a controlled substance?

Based on the review of regulatory documentation, Kaman is not listed as a controlled substance under the U.S. Controlled Substances Act (CSA).

How should Kaman be stored and disposed of?

The official labeling for Kaman (Paromomycin sulfate capsules) mandates specific storage and disposal requirements to maintain product stability and safety.

Required Storage Conditions

The medicine must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). The product must be kept tightly closed in its original container and protected from moisture and light. It is strictly prohibited to freeze the capsules.

Handling and Disposal

For safety, Kaman must be stored out of the sight and reach of children. Unused or expired capsules should not be flushed down the toilet. Disposal must follow regulatory guidelines, preferably using official drug take-back programs or securing the medicine in household trash mixed with an unappealing substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Kaman found in:

A-Z Index: